The Food and Drug Administration announced on Thursday that popular obesity and Type 2 diabetes medications do not have a clear risk of patients developing depression and suicidal thoughts.

The agency published its initial findings after a monthslong review of information from the FDA Adverse Event Reporting System on the entire drug class of GLP1 RAs, which include Ozempic, Wegovy, Mounjaro, and Zepbound.